Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 9/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL964784 | 1.00 | HSD11B1 (0.42) | HSD11B1KMT2AMEN1LMNAKDM4E | |
| SCHEMBL962195 | 0.85 | HPGD (0.32) | HSD11B1KMT2AMEN1LMNA | |
| SCHEMBL960881 | 0.84 | HPGD (0.34) | HSD11B1KMT2AMEN1 | |
| SCHEMBL961465 | 0.82 | ALDH1A1 (0.45) | KMT2AMEN1LMNA | |
| SCHEMBL962486 | 0.76 | HSD11B1 (0.51) | HSD11B1KMT2AMEN1LMNAKDM4E | |
| SCHEMBL962485 | 0.76 | HSD11B1 (0.51) | HSD11B1KMT2AMEN1LMNAKDM4E | |
| SCHEMBL12915091 | 0.74 | HSD11B1 (0.49) | HSD11B1KMT2AMEN1LMNAKDM4E | |
| SCHEMBL12915107 | 0.74 | HSD11B1 (0.49) | HSD11B1KMT2AMEN1LMNAKDM4E | |
| SCHEMBL966396 | 0.73 | HSD11B1 (0.47) | HSD11B1KMT2AMEN1LMNAKDM4E | |
| SCHEMBL961492 | 0.73 | HSD11B1 (0.47) | HSD11B1KMT2AMEN1LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110015196-A1 | LUPEOL-TYPE TRITERPENE DERIVATIVES AS ANTIVIRALS | HETERO RESEARCH FOUNDATION (IN) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015196-A1 | LUPEOL-TYPE TRITERPENE DERIVATIVES AS ANTIVIRALS | MAVS, IRF3, LSS | HSD11B1 115/4885KMT2A 4391/4885MEN1 3268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.